Search hospitals > Maryland > Baltimore
Mercy Medical Center
Claim this profileBaltimore, Maryland 21202
Global Leader in Breast Cancer
Global Leader in Cancer
Conducts research for Hepatitis
Conducts research for Hepatitis C
Conducts research for Liver Cirrhosis
219 reported clinical trials
5 medical researchers
Summary
Mercy Medical Center is a medical facility located in Baltimore, Maryland. This center is recognized for care of Breast Cancer, Cancer, Hepatitis, Hepatitis C, Liver Cirrhosis and other specialties. Mercy Medical Center is involved with conducting 219 clinical trials across 295 conditions. There are 5 research doctors associated with this hospital, such as David Riseberg, Paul Thuluvath, MBBS, MD, FRCP, Teresa Diaz-Montes, M.D., M.P.H, and Armando Sardi, M.D..Area of expertise
1Breast Cancer
Global LeaderHER2 negative
ER positive
Stage IV
2Cancer
Global LeaderStage IV
Stage III
HER2 negative
Top PIs
David RisebergMercy Medical Center1 year of reported clinical research
Studies Breast Cancer
Studies Cancer
11 reported clinical trials
23 drugs studied
Paul Thuluvath, MBBS, MD, FRCPMercy Medical Center3 years of reported clinical research
Studies Liver Cirrhosis
Studies Non-alcoholic Fatty Liver Disease
7 reported clinical trials
10 drugs studied
Teresa Diaz-Montes, M.D., M.P.HMercy Medical Center10 years of reported clinical research
Studies Ovarian Cancer
Studies Ovarian Tumors
1 reported clinical trial
6 drugs studied
Armando Sardi, M.D.Mercy Medical Center10 years of reported clinical research
Studies Ovarian Cancer
Studies Ovarian Tumors
1 reported clinical trial
6 drugs studied
Clinical Trials running at Mercy Medical Center
Breast Cancer
Liver Cirrhosis
Cholangitis
Non-alcoholic Fatty Liver Disease
Hepatitis
Cancer
Primary Biliary Cirrhosis
Fatty Liver Disease
Liver Disease
Fibrosis
Sacituzumab Govitecan
for Triple-Negative Breast Cancer
The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) versus treatment of physician's choice (TPC) in participants with previously untreated, locally advanced, inoperable or metastatic triple-negative breast cancer whose tumors do not express programmed cell death ligand 1 (PD-L1) or in participants previously treated with anti-programmed cell death (ligand or protein) 1 (Anti-PD-(L)1) Agents in the early setting whose tumors do express PD-L1.
Recruiting4 awards Phase 3
Chemotherapy + Hormone Therapy
for Breast Cancer
This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with estrogen receptor (ER)-positive, HER2-negative tumors and 21-gene recurrence score (RS) between 16-25 (for pN0 patients) and 0-25 (for pN1 patients).
Recruiting2 awards Phase 319 criteria
Durvalumab + Chemotherapy
for Breast Cancer
This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint Ultrahigh (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint Ultrahigh Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
Recruiting2 awards Phase 340 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Mercy Medical Center?
Mercy Medical Center is a medical facility located in Baltimore, Maryland. This center is recognized for care of Breast Cancer, Cancer, Hepatitis, Hepatitis C, Liver Cirrhosis and other specialties. Mercy Medical Center is involved with conducting 219 clinical trials across 295 conditions. There are 5 research doctors associated with this hospital, such as David Riseberg, Paul Thuluvath, MBBS, MD, FRCP, Teresa Diaz-Montes, M.D., M.P.H, and Armando Sardi, M.D..